6949 — Pell Bio Med Technology Co Income Statement
0.000.00%
Last trade - 00:00
- TWD8.62bn
- TWD7.70bn
- TWD18.03m
2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS |
Status: | Final | Final | Final |
Revenue | |||
Total Revenue | 14 | 17.2 | 18 |
Cost of Revenue | |||
Gross Profit | -4.37 | -11.3 | -26.1 |
Selling / General / Administrative Expenses | |||
Research And Development | |||
Depreciation and Amortization | |||
Unusual Expense / Income | |||
Total Operating Expenses | 207 | 253 | 429 |
Operating Profit | -193 | -236 | -411 |
Gain / Loss on Sale of Assets | |||
Total Net Non Operating Interest Income / Expense | |||
Other Net Non Operating Costs | |||
Net Income Before Taxes | -189 | -231 | -401 |
Provision for Income Taxes | |||
Net Income After Taxes | -189 | -231 | -401 |
Minority Interest | |||
Net Income Before Extraordinary Items | |||
Net Income | -189 | -230 | -399 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||
Income Available to Common Shareholders Including Extraordinary Items | |||
Diluted Net Income | -189 | -230 | -399 |
Diluted Weighted Average Shares | |||
Basic EPS Including Extraordinary Items | |||
Diluted EPS Including Extraordinary Items | |||
Diluted EPS Excluding Extraordinary Items | |||
Normalised Income Before Taxes | |||
Normalised Income After Taxes | |||
Normalised Income Available to Common Shareholders | |||
Diluted Normalised EPS | -4.16 | -4.98 | -8.62 |
Dividends per Share |